For research use only. Not for therapeutic Use.
Dexpramipexole(CAT: I000259) is the R(+) enantiomer of pramipexole, originally developed as a neuroprotective agent. Unlike its S(-) enantiomer, which is used as a dopamine D2/D3 receptor agonist for treating Parkinson’s disease and restless legs syndrome, dexpramipexole lacks significant dopaminergic activity. Instead, it is known for its ability to reduce oxidative stress and mitochondrial dysfunction, providing potential neuroprotection. Dexpramipexole has been investigated for treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases due to its role in preserving neuronal health. It remains a promising compound in neuroprotection and neurodegenerative disease research.
| CAS Number | 104632-28-2 |
| Synonyms | N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine |
| Molecular Formula | C10H17N3S |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | (6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine |
| InChI | InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m1/s1 |
| InChIKey | FASDKYOPVNHBLU-SSDOTTSWSA-N |
| SMILES | CCCN[C@@H]1CCC2=C(C1)SC(=N2)N |
